ORPEA (ORP.PA)       24.31  -0.07 (-0.29%)

24.31  -0.07 (-0.29%)

FR0000184798 - Common Stock


Fundamental Rating

Taking everything into account, ORP scores 2 out of 10 in our fundamental rating. ORP was compared to 9 industry peers in the Health Care Providers & Services industry. ORP has a bad profitability rating. Also its financial health evaluation is rather negative. ORP has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating


The Piotroski-F score of ORP is 4.00. This is a neutral score and indicates average health and profitability for ORP.
ORP's Return On Assets of 0.34% is worse than the rest of the industry. The industry average Return On Assets is 2.53%. 100% of the industry peers have a better Return On Assets.

ORP's Return On Equity of 1.72% is worse than the rest of the industry. The industry average Return On Equity is 9.04%. 100% of the industry peers have a better Return On Equity.
ORP's Profit Margin of 1.52% is worse than the rest of the industry. The industry average Profit Margin is 2.83%. 88% of the industry peers have a better Profit Margin.
VS Industry

ROA (0.34%) VS Industry: 0% outperformed.

0.34
11.34

ROE (1.72%) VS Industry: 0% outperformed.

1.72
26.15

Profit Margin (1.52%) VS Industry: 12% outperformed.

0.67
16.78

Valuation

Valuation Rating


With a Forward Price/Earnings Ratio of 7.43, the valuation of ORP can be described as cheap.
With a price book ratio of 0.41, ORP is valued rather cheaply.
Compared to an average industry price book ratio of 1.51, ORP is valued rather cheaply. On top of this, ORP is cheaper than 100% of the companies listed in the same industry.

With a Price/Earnings Ratio of 24.07, ORP is valued on the expensive side.
Compared to an average industry Price/Earning Ratio of 14.60, ORP is valued more expensive than its industry peers. On top of this 88% of the companies listed in the same industry are cheaper than ORP!
Compared to an average industry Enterprise Value to EBITDA ratio of 9.89, ORP is valued more expensive than its industry peers. 86% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Earnings (24.07) VS Industry: 12% outperformed.

63.60
6.10

Price/Book (0.41) VS Industry: 100% outperformed.

3.64
0.41

Enterprise Value/ EBITDA (14.69) VS Industry: 14% outperformed.

17.48
3.77

Growth

Growth Rating


When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
The Earnings Per Share is expected to decrease by -2.62% on average over the next 5 years.
ORP shows a small growth in Revenue. In the last year, the Revenue has grown by 9.59%.
The Revenue has been growing slightly by 8.63% on average over the past 5 years.

The Revenue is expected to grow by 4.84% on average over the next 5 years.
ORP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.67%.
ORP shows a very negative growth in Earnings Per Share. Measured over the last 5 years, the EPS has been decreasing by -27.02% yearly.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS-27.02% -33.38% -58.67% -10.23% 0.15% -3.99% -2.62%
Revenue8.63% 7.92% 9.59% 5.68% 6.22% 5.15% 4.84%

Health

Health Rating


ORP has a Piotroski-F score of 4.00. This indicates an average health and profitability for ORP.
ORP has a Current Ratio of 0.68. This is a bad value and indicates that ORP is not financially healthy enough and could expect problems in meeting its short term obligations.
Compared to an average industry Current Ratio of 1.27, ORP is worse placed to pay its short term obligations than its industry peers. 100% of its industry peers have a better Current Ratio.
A Quick Ratio of 0.68 indicates that ORP may have some problems paying its short term obligations.

When comparing the Quick Ratio of ORP to the average industry Current Ratio of 0.96, ORP is less able to pay its short term obligations than its industry peers. 88% of its industry peers have a better Quick Ratio.
ORP has one of the worst Debt to Equity ratios in its industry. 100% of its industry peers require less debt for financing their operations.
Based on the Altman-Z score of 0.45, we must say that ORP is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of ORP to the average industry Altman-Z score of 1.78, ORP is less financially healthy than its industry peers. 100% of its industry peers have a better Altman-Z score.
VS Industry

Debt/Equity (2.63) VS Industry: 0% outperformed.

2.63
0.04

Quick Ratio (0.68) VS Industry: 12% outperformed.

0.62
1.73

Current Ratio (0.68) VS Industry: 0% outperformed.

0.68
2.54

Altman-Z (0.45) VS Industry: 0% outperformed.

0.45
5.99

Dividend

Dividend Rating


No dividends for ORP!.

ORP Daily chart

ORPEA24.31

EPA:ORP (8/10/2022, 10:41:12 AM)-0.07 (-0.29%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Health Care Equipment & Services
GICS Industry Health Care Providers & Services
Earnings (Last) N/A N/A Earnings (Next) N/A N/A
Ins Owners N/A Inst Owners N/A
Market Cap 1.57B Analysts 72.86
Valuation
PE 24.07 Fwd PE 7.43
PEG (NY) N/A PEG (5Y) N/A
P/S 0.37 P/B 0.41
EV/EBITDA 14.69
Profitability
ROA 0.34% ROE 1.72%
PM 1.52 Asset Turnover 0.23
Growth
EPS 1Y -58.67% EPS 3Y -33.38%
EPS 5Y -27.02% EPS growth Q2Q -143.98%
EPS Next Y -10.23% EPS Next 2Y 0.15%
EPS Next 3Y -3.99% EPS Next 5Y -2.62%
Revenue growth 1Y 9.59% Revenue growth 3Y 7.92%
Revenue growth 5Y 8.63% Revenue growth Q2Q 10.44%
Revenue Next Year 5.68% Revenue Next 2Y 6.22%
Revenue Next 3Y 5.15% Revenue Next 5Y 4.84%
Health
Current Ratio 0.68 Quick Ratio 0.68
Altman-Z 0.45 F-Score 4
Debt/Equity 2.63
Dividend
Dividend Yield N/A Dividend Growth N/A
DP 89.23% Ex-Date N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the EuroNext

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the EuroNext

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the EuroNext

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the EuroNext